Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

More documents

Recommendations

Info

190 Special Solidarity Fund KCE Reports 133 Updates of the classification system require a formal decision of the French government and the preliminary advice of a Commission, composed of healthcare providers representatives and health insurers (Comité économique des produits de Santé). 9.14.4 List of Chronic Diseases (Affection de Longue Durée - ALD 30) Accident vasculaire cérébral invalidant Aplasie médullaire et autres cytopénies chroniques Artériopathies chroniques avec manifestations ischémiques Bilharzioze compliquée Insuffisance cardiaque grave, troubles du rythme graves, cardiopathies valvulaires graves, cardiopathies congénitales graves Maladies chroniques actives du foie et cirrhoses Déficit immunitaire primitif grave nécessitant un traitement prolongé, infection par le Virus de l'Immuno-déficience Humaine (VIH) Diabète de type 1 et diabète de type 2 Formes graves des affections neurologiques et musculaires (dont myopathie), épilepsie grave Hémoglobinopathies, hémolyses, chroniques constitutionnelles et acquises sévères Hémophilies et affections constitutionnelles de l'hémostase graves Hypertension artérielle sévère Infarctus coronaire Insuffisance respiratoire chronique grave Maladie d'Alzheimer et autres démences Maladie de Parkinson Maladies métaboliques héréditaires nécessitant un traitement prolongé spécialisé Mucoviscidose Néphropathie chronique grave et syndrome néphrotique primitif Paraplégie Périarthrite noueuse, lupus érythémateux aigu disséminé, sclérodermie généralisée évolutive Polyarthrite rhumatoïde évolutive grave Affections psychiatriques de longue durée Rectocolite hémorragique et maladie de Crohn évolutives Sclérose en plaques Scoliose structurale évolutive (dont l'angle est égal ou supérieur à 25 degrés) jusqu'à maturation rachidienne Spondylarthrite ankylosante grave Suites de transplantation d'organe Tuberculose active, lèpre Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique.
KCE Reports 133 Special Solidarity Fund 191 9.15 INTERNATIONAL COMPARISON: THE NETHERLANDS 9.15.1 Sources 9.15.1.1 Interviews 9.15.1.2 • 1 telephone interview with Mr. Harrie Kemna, Senior Advisor Pharmaceutics, Association of Dutch Hospitals (NVZ – Vereniging van Ziekenhuizen), September 2009 • 2 telephone interviews with Mrs. Anneke Prenger, Senior Advisor Pharmaceutics, Dutch Federation Health Insurers (Zorgverzekeraars Nederland), September 2009 • 1 telephone interview with Mrs. Jolande Huizer, Steering Committee Orphan Drugs (Stuurgroep voor Weesgeneesmiddelen, September 2009 Websites • Dutch Federation of Health Insurers/Zorgverzekeraars Nederland: http://www.zn.nl/OverZN/index.asp • Files with respect to the reforms of the health system and health Insurance system, NRC Handelsblad: http://www.nrc.nl/dossiers/zorgstelsel/de_zorg_instellingen/ • Dutch Ministry of Health: http://www.minvws.nl/ • Dutch Steering Committee Orphan Drugs (Stuurgroep voor Weesgeneesmiddelen): http://www.weesgeneesmiddelen.nl/ • Dutch Healthcare Insurance Board / College van Zorgverzekeraars: www.cvz.nl • Dutch Federation of Health Insurance Providers / Zorgverzekering Nederland: http://www.zn.nl/OverZN/index.asp • Dutch Organisation for Health research and Healthcare innovation: www.zonmw.nl • Rare Diseases fund: www.zzf.nl • European Observatory on Health Systems and Policies, http://www.euro.who.int/observatory 9.15.1.3 Publications • The Commonwealth Fund, Descriptions of healthcare systems: Denmark, France, Germany, The Netherlands, Sweden and the United Kingdom, 2008 • The Commonwealth Fund, Descriptions of healthcare systems: Denmark, France, Germany, The Netherlands, Sweden and the United Kingdom, 2008 • Steering Committee Orphan Drugs, Beschikbaarheid van Geneesmiddelen voor Zeldzame Ziekten, www.weesgeneesmiddelen.nl,2009
Page 1 and 2:
Optimalisatie van de werkingsproces
Page 3 and 4:
Optimalisatie van de werkingsproces
Page 5 and 6:
KCE reports 133A Bijzonder Solidari
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17:
Page 20 and 21:
2 Special Solidarity Fund KCE Repor
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
10 Special Solidarity Fund KCE Repo
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100 Special Solidarity Fund KCE Rep
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159: 140 Special Solidarity Fund KCE Rep
Page 230 and 231: Wettelijk depot : D/2010/10.273/44
Page 232 and 233: 37. HTA Magnetische Resonantie Beel
Page 234: 108. Tiotropium in de behandeling v
show all

Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?